Marijuana: Cantor Fitzgerald Raises GW Pharma's Target To $235 Following Epidiolex Approval
S E E D E D C O N T E N T
The U.S. Food and Drug Administration on Monday announced the approval of GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)’s cannabidiol-based Epidiolex for the treatment of two rare childhood-onset forms of epilepsy that are commonly treatment-resistant.
“The acknowledgement by the FDA of cannabis’ potential medical efficacy is likely to rekindle debates as to the proper classification of cannabis, and particularly cannabidiol (CBD), the main active ingredient in GW’s product, under the Controlled Substances Act,” Harrison Phillips, vice president at Viridian Capital Advisors, told Benzinga back in April.
The Analyst
Cantor Fitzgerald analysts Elemer Piros and Justin Kim reiterated an Overweight rating on the stock, and increased their 12-month price target from $205 to $235/ADS.
Note: the stock closed today at just over $144
Tags
Who is online
46 visitors
“With the approval, GW Pharmaceuticals was granted a rare pediatric disease priority review voucher,” the note said.
Epidiolex has become the first FDA-approved drug containing a purified drug substance derived from cannabis.
“While Epidiolex is derived from cannabidiol (CBD), the FDA noted it does not cause intoxication or euphoria that is seen in tetrahydrocannabinol (THC). Additionally, Epidiolex is the first FDA approval for the treatment of patients with Dravet syndrome, and the first in a new category of anti-epileptic drugs (AEDs),” the analysts said.
Sadly, I had owned this stock in the past but got impatient and sold it!